Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity

Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity

BackgroundThe quality of life of patients at all stages of hematological malignancy is greatly affected by the disease and its treatment. There is a wide range of health-related quality of life (HRQoL) issues important to these patients. Any new instrument developed to measure HRQoL of such patients...

Full description

Bibliographic Details
Main Authors: Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Sam Salek
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Pharmacology
Subjects:
hematological malignancy
HM-PRO
quality of life
symptoms
content validity
clinical practice
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00209/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00209/full

Similar Items